Authors

Tara H. Budinetz, D.O., Jessica S. Mann, M.D., Daniel W. Griffin, M.D., Claudio A. Benadiva, M.D., John C. Nulsen, M.D., Lawrence L. Engmann, M.D.

Volume 102, Issue 3, Pages 753-758

Abstract

Objective:

To compare the rate of congenital anomalies, obstetrical complications, and neonatal complications in antagonist cycles where either GnRH agonist (GnRHa) or hCG was used for final oocyte maturation.

Design:

Retrospective cohort study.

Setting:

University-based tertiary fertility center.

Patient(s):

Three hundred ninety-two women under 40 years of age who underwent controlled ovarian stimulation using a GnRH antagonist protocol and who had final oocyte maturation triggered with either a GnRHa or hCG that resulted in pregnancy and delivery after 16 weeks’ gestation.

Intervention(s):

GnRHa versus hCG trigger of final oocyte maturation.

Main Outcome Measure(s):

Congenital anomaly rates, obstetrical complications, and neonatal complications.

Result(s):

There were no significant differences in the rate of congenital anomalies between GnRHa and hCG trigger (6.6 vs. 9.2%). There were also no differences in the maternal complications (27.6 vs. 20.8%) or neonatal complications (19.7 vs. 20.0%) between the GnRHa trigger and hCG trigger groups.

Conclusion(s):

GnRHa trigger does not affect the rate of congenital anomalies or obstetrical or neonatal complications and remains a viable option in the prevention of ovarian hyperstimulation syndrome.

Read the full text at: http://www.fertstert.org/article/S0015-0282(14)00493-2/fulltext